Shamburg News · 8-K filed Oct 19, 2026, 7:05 AM EDT

EyePoint's LUCIA Phase 3 Wet AMD Trial Misses Primary Endpoint for DURAVYU

EYPT · EyePoint, Inc.

  • Other event
  • Reg FD disclosure
  • Materiality: high

On October 19, 2026, EyePoint, Inc. announced topline results from LUCIA, its second pivotal Phase 3 trial of DURAVYU for wet age-related macular degeneration. The trial did not achieve the primary endpoint of statistical non-inferiority in mean change in best corrected visual acuity versus on-label aflibercept control, though key secondary endpoints were met, including a 38% reduction in treatment burden. The company also posted an updated investor presentation the same day, and DME Phase 3 topline data remain anticipated in Q4 2027.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 8.01, 9.01, accession 0001193125-26-424644.

Written from the filing by Shamburg Markets. Figures are as reported by the company.